RenovoRx Inc logo

RenovoRx Inc(RNXT)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$0.94
11/20/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for RNXT

11/20/2026: RNXT (1-star) is currently NOT-A-BUY. Pass it for now.

RenovoRx Inc is a clinical-stage biopharmaceutical and medical device company that develops targeted oncology therapies using its proprietary Trans-Arterial Micro-Perfusion platform and FDA-cleared RenovoCath device. The company's primary operational strength lies in its growing commercial adoption across cancer treatment centers and expanding device sales. Its core investment story centers on advancing its Phase III TIGeR-PaC trial for pancreatic cancer and scaling applications into other solid tumors. Key risks include ongoing cash burn, execution dependencies on clinical trials, and intense competition in localized oncology. The stock suits growth-oriented or tactical investors comfortable with biotech volatility while monitoring clinical and commercial progress.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitOffers high-growth potential tied to clinical catalysts, offset by early-stage commercial scale.
Momentum investorStrong fit while signal remains positiveAttractive for tactical trading around clinical trial updates and commercial expansion announcements when technical momentum is strong.
Value investorWeak fitLacks current profitability and traditional value metrics due to ongoing clinical development investments.
Dividend investorWeak fitThe company does not pay dividends and retains all capital for business growth.
Low-risk investorWeak fitExhibits high stock price volatility and regulatory binary risks typical of micro-cap biotechnology stocks.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighMicro-cap clinical-stage stocks experience sharp price swings based on news flow and market sentiment.
Valuation riskHighValuation relies heavily on future clinical trial outcomes and projected commercial milestones.
Competition risk (localized oncology delivery)Medium / highFaces competition from other specialized device and therapy developers attempting localized cancer treatments.
Business qualityMediumBacked by patented proprietary technology but constrained by early commercial scale.
Dividend incomeLow / noneNo dividend distributions are paid to shareholders.
Execution riskHighSuccess depends on clinical trial execution, regulatory approvals, and commercial center adoption.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 45.45M USD
Price to earnings Ratio -
1Y Target Price 7.25
Price to earnings Ratio -
1Y Target Price 7.25
Volume (30-day avg) 466.3K shares
Beta 1.17
52 Weeks Range 0.77 - 2.59
Updated Date 11/21/2026
52 Weeks Range 0.77 - 2.59
Updated Date 11/21/2026
Dividends yield (FY) -
Basic EPS (TTM) -0.31

Sector & Industry Intelligence

Sector

Healthcare

Constructive
Sentiment
Strong Bullish
Momentum
BUY Breadth Improving
BUY participation
55.2%
Active BUY / eligible
53 / 96
30-Day BUY Count Change
+19
Market state
Strong Bullish

More qualifying stocks are receiving or maintaining BUY advisories, indicating improving market participation.

Industry

Biotechnology

BUY participation
43.2%
Active BUY / eligible
19 / 44
30-Day BUY Count Change
+12

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Rolling Over
PRICE PATH

Rolling Over

The price momentum is slowing down and beginning to turn downward.

Highly Choppy
PRICE STABILITY

Highly Choppy

The stock has experienced frequent, large price swings that make its near-term movement less predictable.

Analysis of Past Performance

Type Stock
Historic Profit -33.61%
Avg. Invested days 20
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/20/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
RNXT receives a 3-star rating, supported by solid analyst coverage. The rating is constrained by soft unit economics, and weak price momentum.

Company Fundamentals

★★★★★
RNXT has moderate overall fundamentals (3 stars), with soft financial health, moderate growth momentum, and moderate ownership. In FY2025 versus FY2024, strong revenue growth (+2511.6%) is partially offset by negative earnings growth (-26.7%), weak cash generation (FCF margin -977.3%), weak profitability (net margin -994.5%).

Financial Health Rating

★★★★★
RNXT's financial health is soft, with the relatively strongest area being moderate liquidity, including working-capital and asset support (WC/assets 73.3%). Cash strength is soft (2 stars), which helps explain the 2-star overall score.

Growth Momentum Score

★★★★★
Revenue growth is RNXT's strongest growth driver at +2511.6% FY2025 versus FY2024 (strong, 5 stars). By comparison, while earnings growth (-26.7%, negative) and free-cash-flow growth (-20.1%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 25.4% (moderate) and 87.8% of outstanding shares are publicly tradable (strong). Insider ownership of 3.47% provides only moderate management-shareholder alignment.

Top 5 Institutional Investors

AIGH Capital Management, LLC 9.13%
Bleichroeder LP 3.45%
Vanguard Capital Management, LLC 2.99%
Renaissance Technologies Corp 2.32%
Geode Capital Management, LLC 0.88%

Unit Economics (Per $1K Revenue)

★★★★★
RNXT generates approximately $709 of gross profit, $-11,140 of operating income, and $-9,773 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 2-star rating, with weak cash conversion and strong capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.00%

Quantitative Style Profile

★★★★★
RNXT has a liquid profile. Weak momentum is the primary drawback, while soft valuation.

Style Classification

Quality Focused

Small / Mid Cap RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Medical Device SalesCommercial sales and repeat orders of the RenovoCath device to authorized cancer treatment centers.Generates direct device revenue while clinical trials advance toward potential therapeutic approvals.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Valuation

Trailing PE -
Forward PE -
Enterprise Value 40.62M
Price to Sales(TTM) 16.37
Enterprise Value 40.62M
Price to Sales(TTM) 16.37
Enterprise Value to Revenue 15.59
Enterprise Value to EBITDA -4.72
Shares Outstanding 48.25M
Shares Floating 42.38M
Shares Outstanding 48.25M
Shares Floating 42.38M
Percent Insiders 3.47
Percent Institutions 25.44

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.